Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!
- PMID: 37738952
- DOI: 10.1016/j.chembiol.2023.07.020
Repurposing SGLT2 inhibitors for autoimmune diseases? YES, WE MAY!
Abstract
T cells play a key role in driving autoimmunity, with alterations in metabolism powering their effector function. In the July 11 issue of Cell Metabolism, Jenkins et al.1 describe how a type 2 diabetes drug, canagliflozin, can be repurposed for the treatment of autoimmune disorders through metabolic reprogramming of the T cell response.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity.Cell Metab. 2023 Jul 11;35(7):1132-1146.e9. doi: 10.1016/j.cmet.2023.05.001. Epub 2023 May 24. Cell Metab. 2023. PMID: 37230079
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical